The National Institutes of Health reported this week that it launched a clinical trial evaluating a combination of antibodies in people with HIV.
The early-stage study is designed to assess whether periodic infusions of two HIV-specific antibodies are safe in people living with HIV. Researchers also plan to gather preliminary data assessing how effectively the infusions suppress HIV after patients stop taking antiretroviral therapy.
Get the full story at our sister site, Drug Delivery Business News.
